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Excess Stroke Among Hypertensive Men and Women
Attributable to Undertreatment of Hypertension
Olaf H. Klungel, PhD; Bruno H.C. Stricker, PhD; Arsenio H.P. Paes, PhD; Jacob C. Seidell, PhD;
Albert Bakker, PhD; Zolta´n Voko´, MD; Monique M.B. Breteler, PhD; Anthonius de Boer, PhD
Background and Purpose—Most population-based studies indicate that a considerable proportion of hypertensive subjects
are undertreated and that undertreatment is more prevalent among hypertensive men than among hypertensive women.
The aim of our study was to investigate the consequences of undertreatment of hypertension for women and men in
terms of stroke occurrence.
Methods—Approximately 45 000 men and women aged $20 years were examined in 2 population-based studies in the
Netherlands. A cohort of 2616 hypertensive subjects (pharmacologically treated hypertensives and untreated hyperten-
sives who needed pharmacological treatment according to the severity of their hypertension and the coexistence of
additional cardiovascular risk factors) was selected for a follow-up study. Follow-up (mean duration, 4.6 years) was
complete for 2369 (91%) of the enrolled hypertensive subjects.
Results—Compared with treated and controlled hypertensives, the relative risks of stroke for treated and uncontrolled
hypertensives and for untreated hypertensives who needed treatment were 1.30 (95% CI, 0.70 to 2.44) and 1.76 (95%
CI, 1.05 to 2.94), respectively. These relative risks and the prevalence of (undertreated) hypertension in the total
population of 45 000 subjects were used to estimate the number of strokes in the Netherlands attributable to
undertreatment. Among hypertensive men and women aged $20 years in the Netherlands, the proportions of strokes
attributable to treated but uncontrolled blood pressure were 3.1% (95% CI, 25.2% to 18.7%) and 4.1% (95% CI, 27.2%
to 20.7%), respectively. For untreated hypertensive men and women who should have been treated, these proportions
were 22.8% (95% CI, 0.8% to 38.4%) and 25.4% (95% CI, 0.5% to 42.5%), respectively.
Conclusions—Increasing the detection of hypertension and improving adherence to current guidelines might prevent a
considerable proportion of the incident strokes among hypertensives. The potential impact of achieving control of blood
pressure in patients already being treated on the reduction of strokes requires further investigation. (Stroke.
1999;30:1312-1318.)
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Hypertension is one of the most important risk factors forcardiovascular diseases in general and for cerebrovas-
cular diseases in particular.1 Although the beneficial effect of
pharmacological treatment of hypertension on the incidence
of coronary heart diseases and cerebrovascular diseases has
been demonstrated in several controlled clinical trials,2 most
population-based studies indicate that a large proportion of
treated hypertensive patients still have elevated blood pres-
sure,3 and a considerable proportion of hypertensive patients
are not treated with antihypertensive drugs.4 However, not all
hypertensives need pharmacological treatment because, ac-
cording to several guidelines on the management of hyper-
tension, this depends on the severity of hypertension and in
moderate hypertension may depend on the coexistence of
additional cardiovascular risk factors.5–7 In a population-
based study among men and women aged 20 to 59 years in
the Netherlands, we demonstrated that approximately 42%
and 29% of the pharmacologically treated men and women,
respectively, still had elevated blood pressure levels. Of those
hypertensive men and women not treated pharmacologically,
53% and 34%, respectively, should have been treated when
additional cardiovascular risk factors and the severity of
hypertension were taken into account.8
The consequences of undertreatment of hypertension in
terms of cardiovascular disease occurrence have been studied
in observational studies. However, these studies had several
limitations. First, most studies were restricted to either
uncontrolled blood pressure among treated hypertensives9–12
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or to untreated hypertension.13–19 Second, in none of the
studies was the coexistence of additional cardiovascular
disease risk factors taken into account to assess the need for
pharmacological treatment. Finally, in most of these studies,
treated hypertensives were compared with the remainder of
the population or normotensive controls9,13–20 or with un-
treated hypertensives irrespective of their need for treat-
ment.13,14 Thus, the reference groups in these studies were not
comparable with the treated hypertensives with respect to risk
of cardiovascular disease, and this may have led to confound-
ing by the indication for the treatment of hypertension.21
The aim of our study was to estimate the proportion of
incident strokes attributable to undertreatment of hyperten-
sion in men and women, taking into account the shortcomings
of previous studies.
Subjects and Methods
Data
For the present study we used data from 2 population-based studies
in the Netherlands. The first study, the Monitoring Project on
Cardiovascular Risk Factors, was started in 1987 as a cross-sectional
study in Amsterdam, Maastricht, and Doetinchem. In Doetinchem
this study was continued as a prospective follow-up study by
reexamining the subjects examined in 1987 again in 1993. The
second study, the Rotterdam Study, was started in 1990 in Rotterdam
as a population-based prospective follow-up study.
The Monitoring Project on Cardiovascular
Risk Factors
This study was conducted from 1987 to 1991. Each year a new
random sample of men and women aged 20 to 59 years in
Amsterdam, Maastricht, and Doetinchem was selected. The design
of this study has been described in detail elsewhere.22 The overall
response rate in Amsterdam, Maastricht, and Doetinchem was 45%,
58%, and 62%, respectively. Several characteristics such as educa-
tional level, smoking, alcohol use, height, and weight of nonrespon-
dents and respondents have been evaluated in previous studies.8 The
results of these studies suggested that no substantial selection had
taken place with respect to these characteristics.
The Rotterdam Study
This study on the occurrence and determinants of chronic disabling
diseases at older ages was started in 1990. All 10 275 residents of a
suburb of Rotterdam aged $55 years were invited to participate;
7983 (78%) subjects agreed to participate. The design of this study
has been described in detail elsewhere.23 The baseline measurements
took place until 1993.
Baseline Measurements
Information on demographic variables, current health status, medical
history, family history of diseases, smoking habits, and current use of
medication was obtained during a home interview in the Rotterdam
study, whereas self-administered questionnaires were used in the
Monitoring Project on Cardiovascular Risk Factors. The self-
administered questionnaires were checked at the study center with
the participant for completeness. In both studies the physical exam-
inations were performed by either trained technicians or physicians
according to a standardized protocol. Blood pressure, weight, and
height were measured, and blood was drawn for total cholesterol and
HDL cholesterol determination. A random zero sphygmomanometer
was used to measure blood pressure twice with the subject in sitting
position. Systolic blood pressure (SBP) was recorded at the appear-
ance of sounds (first-phase Korotkoff), and diastolic blood pressure
(DBP) was recorded at the disappearance of sounds (fifth-phase
Korotkoff). For the analyses, we used the mean of 2 blood pressure
measurements.
Follow-Up
For this study, we selected subjects who were treated pharmacolog-
ically for hypertension and subjects who were untreated but in need
of pharmacological treatment for hypertension (see Definitions) at
the baseline measurement in Rotterdam (1990–1993) and Doet-
inchem (1987–1991). The follow-up period in both studies started at
the baseline examination and lasted until April 1, 1996, in Rotter-
dam, and until January 1, 1996, in Doetinchem. Information on fatal
and nonfatal strokes was obtained through patient records of general
practitioners (GPs) and the GPs’ archives of specialists’ reports.
Definitions
Hypertension was defined as DBP $95 mm Hg and/or SBP
$160 mm Hg and/or use of antihypertensive drugs for hypertension.
Subjects who said that they used blood pressure–lowering drugs and
mentioned at least 1 drug with an approved indication for the
treatment of hypertension were considered pharmacologically treated
for hypertension. With regard to cardiovascular drug use, it was
previously demonstrated that concordance between medication use
according to patient interview and pharmacy records is very
high.24,25 Three categories of hypertensives were distinguished
according to the Dutch guidelines for the management of hyperten-
sion.5 First, the reference group was defined as pharmacologically
treated hypertensives whose blood pressure was below the treatment
goal of the Dutch guidelines (DBP #90 mm Hg and SBP
#160 mm Hg). The second group included pharmacologically
treated hypertensives whose blood pressure was above this treatment
goal (DBP .90 mm Hg or SBP .160 mm Hg). The third group
consisted of untreated hypertensives who need pharmacological
treatment when the coexistence of additional cardiovascular risk
factors was taken into account. According to the Dutch guidelines,
hypertension should be treated pharmacologically when the DBP is
between 100 and 105 mm Hg and 1 or more cardiovascular risk
factors are present, or when the SBP is between 160 and 180 mm Hg
and 1 or more cardiovascular risk factors are present, or when DBP
or SBP are .105 mm Hg or .180 mm Hg, respectively. The
following additional cardiovascular risk factors should be evaluated
according to these guidelines: sex (male), current smoking, hyper-
cholesterolemia (total cholesterol $6.5 mmol/L), diabetes, target
organ disease, age $60 years, and cardiovascular disease among
parents or sisters or brothers aged ,60 years.
Strokes that could be confirmed by specialists’ letters to the GPs
and strokes that were certain according to the GP were included for
the analysis, whereas events that were probable according to the GP
were excluded. The end point of interest was a first or recurrent fatal
or nonfatal stroke (International Classification of Diseases, Tenth
Revision codes I60 to I69), excluding transient ischemic attacks
(TIA) during follow-up.
History of cardiovascular disease was defined as a self-reported
history of any cardiovascular disease or written information from the
GPs that indicated presence of any cardiovascular disease, excluding
cerebrovascular diseases. History of cerebrovascular disease was
defined as a self-reported history of stroke or TIA, confirmed by
written information from the GPs.
Analyses
Estimation of Risk of Stroke Attributed to Undertreatment
of Hypertension
To study the association between undertreatment and incidence of
stroke, the Cox proportional hazards model was used, and multivar-
iately adjusted relative risks (RRs) and their 95% CIs26 were
calculated. Analyses were initially performed separately for the
Doetinchem study and the Rotterdam study to evaluate effect-
modification due to differences in study design. The RRs of
undertreatment of hypertension for the occurrence of stroke were
virtually the same in the Doetinchem study and the Rotterdam study.
Therefore, the results from the combined analysis are presented.
In addition to the evaluation of all subjects simultaneously,
subgroup analyses were performed after exclusion of patients with-
out a history of cerebrovascular disease and after exclusion of
Klungel et al Undertreatment of Hypertension and Stroke 1313
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patients with any history of cardiovascular disease. Furthermore,
men and women and subjects aged ,80 and $80 years (the efficacy
of antihypertensive treatment at $80 years is unknown2) were
analyzed separately.
All RR estimates were adjusted for age, history of diabetes, total
cholesterol, body mass index, smoking, and history of cardiovascular
disease. When men and women were analyzed together, adjustments
were also made for sex, and in the analysis of all subjects irrespective
of a history of cerebrovascular disease, adjustments were also made
for a history of stroke or TIA. For the adjustment of RRs, smoking
was categorized into never, former, or current smoking.
Estimation of Prevalences of Undertreatment
of Hypertension
Age- and sex-specific prevalences of hypertension, treated and
controlled hypertension, treated but uncontrolled hypertension, and
untreated hypertension that should be treated were estimated among
all subjects who were examined in all 4 cities in both population
studies. These prevalence estimates were used to compute the
number of subjects within these categories of hypertensives in the
whole Dutch population.
Estimation of the Number of Incident Strokes Attributable
to Undertreatment of Hypertension
Age- and sex-specific incidence rates of stroke among all hypertensives,
treated and controlled hypertensives, treated but uncontrolled hyperten-
sives, and untreated hypertensives who should be treated were computed
(PYRS version 1.2) to estimate the number of incident strokes in these
categories of hypertensives in the Netherlands in 1994. This was done
by multiplying the age- and sex-specific estimated numbers of subjects
within the different categories of hypertensives in the Netherlands in
1994 by the corresponding age- and sex-specific incidence rates.
Subsequently, we estimated the proportions of incident strokes attribut-
able to treated but uncontrolled blood pressure and untreated hyperten-
sion that should be treated within each of these categories of undertreat-
ment as the ratio (RR21)/RR. The adjusted RRs of exposed persons
(treated but uncontrolled hypertensives or untreated hypertensives who
should be treated) compared with unexposed persons (treated and
controlled hypertensives) were used for the RR. These proportions were
used to estimate the absolute number of incident strokes attributable to
both types of undertreatment. Finally, these attributable numbers of
incident strokes were expressed as percentages of the total number of
incident strokes among all hypertensive subjects. We estimated 95% CIs
of the attributable number of incident strokes according to the method of
Rothman and Greenland.27
Results
Study Population
A total of 44 571 subjects (12 448 in Doetinchem, 11 488 in
Amsterdam, 12 652 in Maastricht, and 7983 in Rotterdam)
were examined in both population studies. After exclusion of
pregnant women (n5306) and subjects with missing data
(n51665), 42 600 subjects remained available for the estima-
tion of prevalences of hypertension and undertreatment of
hypertension.
Hypertension was prevalent among 2072 subjects (28.9%)
of the Rotterdam study and among 1096 subjects (9.4%) in
Doetinchem. Subjects who did not need antihypertensive
drug treatment according to the guidelines (n5552) were
excluded from the analysis. Therefore, our study population
comprised 2616 subjects pharmacologically treated for hy-
pertension or untreated for hypertension but in need of
pharmacological treatment. Follow-up was complete for 2369
subjects (90.6%).
The differences in baseline characteristics between those
lost to follow-up and those for whom follow-up was complete
were negligible (data not shown).
The number of hypertensives who were treated pharmaco-
logically and had DBP ,90 mm Hg and SBP ,160 mm Hg
was 879, whereas 482 subjects were treated pharmacologi-
cally but had DBP .90 mm Hg or SBP .160 mm Hg, and
1008 subjects were inappropriately not treated pharmacolog-
TABLE 1. Baseline Characteristics of Men and Women Aged >20 Years by
Classification of Undertreatment of Hypertension
Treated,
Controlled*
Treated,
Uncontrolled†
Untreated but Should
Be Treated
No. of subjects 879 482 1008
Women 593 (67.5%) 312 (64.7%) 538 (53.4%)
Age (SD), y 65.8 (10.7) 65.3 (13.0) 66.6 (14.3)
Diabetes 59 (6.7%) 42 (8.7%) 75 (7.4%)
Smoking
Never 360 (42.3%) 216 (45.5%) 395 (40.2%)
Current 170 (20.1%) 104 (21.9%) 233 (23.7%)
Former 318 (37.5%) 155 (32.6%) 354 (36.1%)
Total cholesterol, mmol/L 6.6 (1.2) 6.5 (1.2) 6.6 (1.3)
History of cardiovascular diseases‡ 218 (24.8%) 103 (21.4%) 171 (17.0%)
History of TIA 39 (4.6%) 21 (4.4%) 28 (2.9%)
History of stroke 30 (3.4%) 23 (4.8%) 27 (2.7%)
Body mass index, kg/m2 27.7 (4.0) 28.1 (4.3) 26.8 (3.8)
DBP, mm Hg 75.6 (8.8) 89.2 (11.9) 88.5 (13.6)
SBP, mm Hg 135.5 (14.3) 164.1 (19.7) 169.0 (14.9)
Mean duration of follow-up, y 4.8 (1.7) 4.7 (1.8) 4.3 (1.6)
*Controlled blood pressure, DBP #90 mm Hg and SBP #160 mm Hg.
†Uncontrolled blood pressure, DBP .90 mm Hg or SBP .160 mm Hg.
‡Excluding TIA and strokes.
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ically for hypertension. Baseline characteristics of all 2369
hypertensive men and women stratified by these 3 categories
are listed in Table 1. Most risk factors were evenly distributed
across these categories. One important difference was a
higher prevalence of past cardiovascular disease (excluding
cerebrovascular disease) among pharmacologically treated
hypertensives compared with untreated hypertensives who
should have been treated. This difference was more pro-
nounced for men than for women (data not shown). Preva-
lence of past cerebrovascular disease was also slightly higher
for pharmacologically treated hypertensives.
Undertreatment of Hypertension and Risk
of Stroke
During the follow-up period (mean duration, 4.6 years), 40
men and 68 women experienced a first or recurrent stroke.
The number of fatal stroke events was 2 for men and 15 for
women.
The crude incidence rates of stroke among treated hyper-
tensives with controlled blood pressure levels, treated hyper-
tensives with uncontrolled blood pressure levels, and un-
treated hypertensives who should have been treated were 6.7,
8.2, and 14.0 per 1000 person-years, respectively (Table 2).
Compared with treated hypertensives who had controlled
blood pressure and after adjustment for potential confounding
factors, treated hypertensives who had uncontrolled blood
pressure levels had a 1.30-fold increased risk of stroke (not
statistically significant), whereas untreated hypertensives
who should have been treated had a 1.76-fold increased risk
of stroke (Table 2). These RRs were similar for men and
women. Exclusion of subjects with a history of cerebrovas-
cular disease resulted in slightly increased RRs of treated but
uncontrolled blood pressure and untreated hypertension that
should be treated compared with treated and controlled blood
pressure (1.47 [95% CI, 0.73 to 2.95] and 1.86 [95% CI, 1.04
to 3.33], respectively).
Additional analyses of subjects without any history of
cardiovascular disease resulted in even higher RRs of treated
but uncontrolled blood pressure and untreated hypertension
that should be treated compared with treated and controlled
blood pressure (2.0 [95% CI, 0.8 to 4.6] and 2.3 [95% CI, 1.1
to 4.8], respectively).
For subjects aged ,80 years, the adjusted RRs of stroke of
treated but uncontrolled blood pressure and untreated hyper-
tension that should be treated were 1.4 (95% CI, 0.7 to 2.8)
and 1.7 (95% CI, 0.9 to 3.0), respectively. For subjects aged
$80 years, these RRs were 1.2 (95% CI, 0.2 to 5.6) and 2.6
(95% CI, 0.8 to 9.2), respectively. However, because of the
small numbers we could not further investigate these associ-
ations by age.
Number of Incident Strokes Attributable to
Undertreatment of Hypertension
The incidence rates of stroke after stratification for age, sex,
and categories of hypertension (treated and controlled, treated
but uncontrolled, untreated but should be treated) as derived
from the 2 population studies are presented in Table 3. In both
sexes the incidence rates increased with age. Furthermore,
rates were highest in the untreated hypertensives who should
be treated. The respective age-adjusted prevalences of hyper-
tension (per 100 population), treated and controlled hyperten-
sion (per 100 hypertensives), treated but uncontrolled hyper-
tension (per 100 hypertensives), and untreated hypertension
that should be treated (per 100 hypertensives) were 11.2,
28.2, 15.5, and 39.7 for men, whereas for women these
prevalences were 12.9, 39.4, 18.8, and 32.1. Age- and
sex-specific prevalences were used to calculate the number of
subjects in each of the categories of hypertension for the
whole Dutch population in 1994 (data not shown). These
numbers were subsequently multiplied by the corresponding
incidence rates to estimate the absolute number of strokes in
these categories of hypertensive (Table 3). The number of
TABLE 2. Stroke Incidence Rates (per 1000 Person-Years) Among Hypertensive Subjects
Aged >20 Years and RR Estimates by Classification of Undertreatment of Hypertension
No. of
Subjects
No. of
Events Rate* RR (95% CI)† RR (95% CI)‡
All subjects
Treated, controlled 879 28 6.7 1.00 1.00
Treated, uncontrolled 482 19 8.2 1.24 (0.69–2.22) 1.30 (0.70–2.44)
Untreated, should be treated 1008 61 14.0 2.06 (1.31–3.22) 1.76 (1.05–2.94)
Men
Treated, controlled 286 11 8.4 1.00 1.00
Treated, uncontrolled 170 6 7.3 0.87 (0.32–2.36) 1.29 (0.44–3.76)
Untreated, should be treated 470 23 10.6 1.26 (0.61–2.58) 1.81 (0.77–4.21)
Women
Treated, controlled 593 17 5.9 1.00 1.00
Treated, uncontrolled 312 13 8.7 1.51 (0.73–3.10) 1.31 (0.60–2.87)
Untreated, should be treated 538 38 17.3 2.91 (1.64–5.17) 1.76 (0.90–3.44)
*Per 1000 person-years.
†Unadjusted RR.
‡All RRs are adjusted for age, smoking, total cholesterol, body mass index, history of cardiovascular diseases, and
history of stroke or TIA. RRs for all subjects are also adjusted for sex.
Klungel et al Undertreatment of Hypertension and Stroke 1315
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strokes in women was more than twice the number of strokes
in men.
The age-adjusted proportions of strokes among hyperten-
sive men and women attributable to treated but uncontrolled
blood pressure were 3.1% (95% CI, 25.2% to 18.7%) and
4.1% (95% CI, 27.2% to 20.7%), respectively (Table 4). For
untreated hypertensive men and women who should have
been treated, these proportions were 22.8% (95% CI, 0.8 to
38.4%) and 25.4% (95% CI, 0.5 to 42.5%), respectively.
Among hypertensive subjects aged $20 years in the Nether-
lands in 1994, '26% (1230) of all incident strokes among
hypertensive men and 29% (1975) of all incident strokes
among hypertensive women were attributable to undertreat-
ment of hypertension.
Discussion
In a previous study we showed that during the last decade in
the Netherlands, a considerable proportion of hypertensive
men and women aged 20 to 59 years were undertreated for
hypertension.8 In the present study we investigated the
consequences of undertreatment of hypertension among men
and women aged $20 years with respect to the occurrence of
stroke. We demonstrated that untreated hypertensives who
needed treatment according to the severity of their hyperten-
sion and the presence of additional cardiovascular risk factors
had an increased risk of stroke compared with pharmacolog-
ically treated hypertensives whose blood pressure level was
controlled. Among hypertensive men and women aged $20
years in the Netherlands, '1083 and '1702 incident strokes
per year, respectively (23% and 25% of all incident strokes
among hypertensive men and women, respectively) might be
due to untreated hypertension that should have been treated.
According to an average of several general practice registra-
tions in the Netherlands,28 '13 026 and '15 119 incident
strokes occurred among men and women, respectively, in the
whole Dutch population aged $20 years in 1994. On the
basis of these figures, '8.3% and '11.3% of all incident
strokes among men and women aged $20 years in the
Netherlands were attributable to untreated hypertension that
should have been treated. This is probably an underestimation
since the definition of stroke was more strict in our study than
in these general practice registrations. Because of the impre-
cise RR estimate of treated but uncontrolled blood pressure,
we could not reliably estimate the number of strokes attrib-
utable to this type of undertreatment. However, the attribut-
able fraction due to treated but uncontrolled blood pressure
appears to be much lower than that due to untreated hyper-
tension that should be treated.
Estimations of the proportion of a disease attributable to
exposure are only valid when risk estimates and prevalence
TABLE 3. Incidence Rates (per 1000 Person-Years) and Number of Incident Strokes Among
Hypertensives in the Netherlands in 1994*
Age, y
Hypertension
Treated and
Controlled
Treated but
Uncontrolled
Untreated but
Should Be Treated
Rate No. Rate No. Rate No. Rate No.
Men
20–29 0.0 0 z z z z z z 0.0 0 0.0 0
30–39 0.0 0 0.0 0 0.0 0 0.0 0
40–49 1.1 136 0.0 0 0.0 0 0.0 0
50–59 4.6 706 3.5 173 4.7 141 5.0 225
60–69 8.8 1274 7.6 409 11.5 255 10.0 637
70–79 15.7 1678 10.1 308 11.7 236 18.4 982
$80 29.9 962 26.5 266 0.0 0 38.4 674
.20† 7.5 4757 6.5 1156 6.4 631 10.0 2518
Women
20–29 0.0 0 0.0 0 0.0 0 0.0 0
30–39 0.0 0 0.0 0 0.0 0 0.0 0
40–49 0.0 0 0.0 0 0.0 0 0.0 0
50–59 3.2 463 0.0 0 5.6 170 3.5 88
60–69 3.8 730 2.9 272 3.1 92 3.8 245
70–79 10.6 2061 10.6 796 10.2 422 12.9 963
$80 31.2 3460 15.3 398 22.0 489 43.4 2661
$20† 8.8 6715 4.9 1466 8.2 1172 16.2 3957
Total
$20† 8.2 11 472 5.5 2622 7.5 1804 13.0 6475
Ellipses indicate no person-years in this stratum.
*Incidence rates (per 1000 person-years) were estimated from both population studies. Numbers of strokes were
computed by multiplying the total number of subjects within each age- and sex-specific category of hypertension with
the corresponding incidence rate.
†Weighted for the age distribution of the Dutch population in 1994.
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estimates on which these attributable proportions are based
are unbiased. Therefore, it is important to discuss several
limitations of our study that could potentially have biased our
estimated proportion of strokes attributable to undertreatment
of hypertension.
First, blood pressure was measured only twice on 1
occasion. Because of within-person variability in blood pres-
sure, the group of untreated hypertensives who should be
treated will also comprise normotensive subjects.8,29 Misclas-
sification of normotensives as hypertensive has probably
caused an underestimation of our RR estimates.
A second limitation of this study could be that the results
in part may be caused by confounding by the indication for
the treatment of hypertension. However, we compared a
high-risk group of untreated hypertensives with additional
cardiovascular risk factors with treated and controlled hyper-
tensives, and the differences between untreated hypertensives
who should be treated and treated hypertensives were only
marginal with respect to the traditional cardiovascular risk
factors at baseline. Furthermore, all RR estimates were
adjusted for the potential confounding influence of other
cardiovascular disease risk factors.
Third, it cannot be excluded that treated hypertensives with
controlled blood pressure had lower pretreatment blood
pressure levels than treated but uncontrolled hypertensives.
We could not adjust for this in the analysis. Nonetheless, the
excess risk of treated but uncontrolled blood pressure com-
pared with treated and controlled blood pressure suggests that
lowering blood pressure in hypertensives with uncontrolled
blood pressure would reduce the risk of stroke among these
hypertensive patients.
Fourth, we measured the status of undertreatment only at
baseline, whereas during the follow-up period treatment
could have been started in untreated hypertensives and
control of blood pressure could have been achieved among
treated hypertensives who were uncontrolled at the baseline
measurements. Assuming that it is more likely that untreated
hypertensives are going to be treated during follow-up than
that treatment is stopped in treated hypertensives, the RR of
untreated hypertension that should be treated was probably
underestimated.
Finally, because of the small numbers, some reservation
with regard to the precision of the estimated number of
attributable strokes must be taken into account. The RR of
treated but uncontrolled blood pressure and the number of
strokes attributable to this type of undertreatment were not
statistically significant. However, several other studies also
found an increased risk of stroke among treated hypertensives
with uncontrolled blood pressure compared with those with
controlled blood pressure.9,10,12,20 Furthermore, the increased
risk of treated but uncontrolled blood pressure was consistent
across the subgroups that we studied. Nonetheless, the num-
ber of strokes attributable to treated but uncontrolled blood
pressure should be interpreted with caution.
Although the prevalence of undertreatment of hypertension
was higher for hypertensive men than for hypertensive
women, the proportion of incident strokes due to undertreat-
ment was slightly smaller for men than for women. The
absolute number of incident strokes attributable to undertreat-
ment was also higher for hypertensive women than it was for
hypertensive men. This can probably be explained by the
higher number of elderly women, in particular at ages .70
years. Above this age the incidence rate of stroke was very
high. Another explanation could be that the mortality from
coronary heart disease is much higher among men than
among women.30–32 This could have resulted in a selective
depletion of the pool of men who are at high risk for stroke,
resulting in more women than men at high risk for experi-
encing a stroke event.33
This study provides one of the first estimates of the risk of
stroke in the population in relation to the quality of treatment
of hypertension. Our findings suggest that improvement of
the detection of hypertension and adherence to the current
guidelines on the management of hypertension might prevent
a considerable proportion of incident strokes among hyper-
tensive men and women. The potential impact of achieving
control of blood pressure among those already treated on the
reduction of stroke incidence remains uncertain.
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TABLE 4. Number of Strokes Attributable to Undertreatment of
Hypertension Among Hypertensives in the Netherlands in 1994
Age, y
Treated But
Uncontrolled
Untreated but Should
Be Treated
Total
Undertreated
Men*
20–29 z z z z z z z z z
30–39 z z z z z z z z z
40–49 z z z z z z z z z
50–59 33 (4.6) 97 (13.7) 129 (18.3)
60–69 59 (4.7) 274 (21.5) 333 (26.2)
70–79 55 (3.3) 423 (25.2) 478 (28.5)
$80 z z z 290 (30.1) 290 (30.1)
$20† 147 (3.1) 1083 (22.8) 1230 (25.9)
Women*
20–29 z z z z z z z z z
30–39 z z z z z z z z z
40–49 z z z z z z z z z
50–59 39 (8.5) 38 (8.2) 77 (16.7)
60–69 21 (2.9) 105 (14.4) 127 (17.3)
70–79 98 (4.8) 413 (20.1) 512 (24.9)
$80 114 (3.3) 1145 (33.1) 1259 (36.4)
$20† 273 (4.1) 1702 (25.4) 1975 (29.4)
Total*
$20† 421 (3.7) 2785 (24.3) 3205 (27.9)
Values are number (percent) (percentage of all incident strokes among
hypertensives). Ellipses indicate that no incident strokes were observed in
these age strata.
*Attributable fractions (AF5[RR21]/RR) of incident strokes were estimated
for treated but uncontrolled hypertensive men, women, and all subjects
together (adjusted RR of 1.30 was used) and for untreated hypertensive men,
women, and all subjects together who should be treated (adjusted RR of 1.76
was used). The number of attributable incident strokes was calculated by
multiplying the AFs of both types of undertreatment with the total number of
incident strokes within both types of undertreatment.
†Weighted for the age distribution of the Dutch population in 1994.
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